We propose that SG apparently enhanced anti-cancer potency of cetuximab may be due to the dual interaction on EGFR contributes to enhanced inhibition of EGFR activation: cetuximab interferes with the tethered (closed) conformation while SG interferes with the un-tethered (extended) conformation. This evidence concerns the gene EGFR and cancer.